By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GnuBio announced today it obtained a worldwide license to microfluidics- and emulsion-based methods for nucleic acid analysis.

The technology, which was licensed from the laboratory of David Weitz, one of the founders of GnuBio, will be used by the startup firm to develop its DNA sequencer.

Weitz is a professor of physics and applied physics at Harvard University.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.